Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 6/20 | 0.77 |
| ▸ | ORAI1 | Q96D31 | 6/20 | 0.77 |
| ▸ | EED | O75530 | 11/20 | 0.42 |
| ▸ | SUZ12 | Q15022 | 7/20 | 0.40 |
| ▸ | EZH2 | Q15910 | 7/20 | 0.40 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.40 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14150171 | 0.87 | STIM1 (1.00) | STIM1ORAI1EEDSUZ12EZH2 | |
| SCHEMBL12156003 | 0.83 | IL2 (0.56) | STIM1ORAI1 | |
| SCHEMBL14225952 | 0.81 | STIM1 (0.84) | STIM1ORAI1GABRA5 | |
| SCHEMBL14225939 | 0.81 | STIM1 (0.77) | STIM1ORAI1EEDSUZ12EZH2 | |
| SCHEMBL12155985 | 0.80 | NPC1 (0.52) | STIM1ORAI1CCND1CDK6 | |
| SCHEMBL16335301 | 0.80 | STIM1 (0.67) | STIM1ORAI1GABRA5 | |
| SCHEMBL14150223 | 0.79 | STIM1 (1.00) | STIM1ORAI1GABRA5 | |
| SCHEMBL14225978 | 0.79 | STIM1 (0.73) | STIM1ORAI1GABRA5 | |
| SCHEMBL17746853 | 0.78 | STIM1 (0.64) | STIM1ORAI1GABRA5 | |
| SCHEMBL14225921 | 0.78 | STIM1 (0.78) | STIM1ORAI1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-10-20 | — | — | US | disclosed |
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-10-20 | — | — | US | disclosed |
| US-20140309237-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309237-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20130245063-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245063-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20120316182-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120316182-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316182-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885EED 4289/4885 |
| US-20140309237-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885EED 4289/4885 |
| US-20130245063-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885EED 4289/4885 |
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885EED 4289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.